BR0318586A - formulação antidepressiva oral compreendendo ácido acetil-salicìlico para acelerar o inìcio de ação - Google Patents

formulação antidepressiva oral compreendendo ácido acetil-salicìlico para acelerar o inìcio de ação

Info

Publication number
BR0318586A
BR0318586A BRPI0318586-9A BR0318586A BR0318586A BR 0318586 A BR0318586 A BR 0318586A BR 0318586 A BR0318586 A BR 0318586A BR 0318586 A BR0318586 A BR 0318586A
Authority
BR
Brazil
Prior art keywords
onset
action
antagonists
antidepressant
accelerate
Prior art date
Application number
BRPI0318586-9A
Other languages
English (en)
Inventor
Julien Mendlewicz
Philippe Kriwin
Roland Powis De Tenbossche
Original Assignee
Julien Mendlewicz
Philippe Kriwin
Roland Powis De Tenbossche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julien Mendlewicz, Philippe Kriwin, Roland Powis De Tenbossche filed Critical Julien Mendlewicz
Publication of BR0318586A publication Critical patent/BR0318586A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

"FORMULAçãO ANTIDEPRESSIVA ORAL COMPREENDENDO áCIDO ACETIL-SALICìLICO PARA ACELERAR O INìCIO DE AçãO". A presente invenção refere-se a formulação antidepressiva oral compreendendo uma quantidade antidepressiva eficaz de um ou mais agentes ativos antidepressivos farmaceuticamente aceitáveis vantajosamente selecionados do grupo consistindo em SSRI, SNRIs (inibidores da recaptação de serotonina nordralina), antagonistas de CRF, antagonistas de NK1, antagonistas de NK2, antagonistas de NK3 e combinações dos mesmos e uma quantidade eficaz menor do que 50 mg de pelo menos um composto selecionado do grupo consistindo em ácido acetil-salicílico, derivados de ácido acetil-salicíiíco, diaspirina e misturas dos mesmos para redução do início de ação antidepressiva.
BRPI0318586-9A 2003-10-29 2003-10-29 formulação antidepressiva oral compreendendo ácido acetil-salicìlico para acelerar o inìcio de ação BR0318586A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BE2003/000181 WO2005039545A1 (en) 2003-10-29 2003-10-29 Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action

Publications (1)

Publication Number Publication Date
BR0318586A true BR0318586A (pt) 2006-10-17

Family

ID=34468654

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0318586-9A BR0318586A (pt) 2003-10-29 2003-10-29 formulação antidepressiva oral compreendendo ácido acetil-salicìlico para acelerar o inìcio de ação

Country Status (15)

Country Link
EP (1) EP1677772B1 (pt)
JP (1) JP2007509838A (pt)
CN (1) CN1859901A (pt)
AT (1) ATE440597T1 (pt)
AU (1) AU2003280232A1 (pt)
BR (1) BR0318586A (pt)
CA (1) CA2543640C (pt)
CY (1) CY1110572T1 (pt)
DE (1) DE60329034D1 (pt)
DK (1) DK1677772T3 (pt)
EA (1) EA011926B1 (pt)
ES (1) ES2332176T3 (pt)
PT (1) PT1677772E (pt)
SI (1) SI1677772T1 (pt)
WO (1) WO2005039545A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100189797A1 (en) * 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
IT1392333B1 (it) * 2008-12-16 2012-02-28 Giofarma S R L Preparazione farmaceutica per il trattamento di patologie depressive, contenente una proteina con elevato rapporto triptofano/lnaa
GB201002530D0 (en) 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
CN112438991B (zh) * 2019-08-29 2024-03-15 鲁南制药集团股份有限公司 肝素、或其衍生物、或其可药用盐的医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650789A (en) * 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
GB2287404A (en) * 1994-03-15 1995-09-20 Pfizer Antiinflammatory and analgesic compositions
CA2350531A1 (en) * 1998-11-13 2000-05-25 Smriti Iyengar Method for treating pain
WO2000059489A2 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
AU2003229408A1 (en) * 2002-06-10 2003-12-22 Philippe Kriwin Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor

Also Published As

Publication number Publication date
ATE440597T1 (de) 2009-09-15
SI1677772T1 (sl) 2010-01-29
EP1677772A1 (en) 2006-07-12
JP2007509838A (ja) 2007-04-19
CY1110572T1 (el) 2015-04-29
CN1859901A (zh) 2006-11-08
EA200600834A1 (ru) 2006-10-27
CA2543640A1 (en) 2005-05-06
WO2005039545A1 (en) 2005-05-06
DK1677772T3 (da) 2009-12-21
PT1677772E (pt) 2009-11-26
DE60329034D1 (de) 2009-10-08
CA2543640C (en) 2010-06-01
EP1677772B1 (en) 2009-08-26
AU2003280232A1 (en) 2005-05-11
ES2332176T3 (es) 2010-01-28
EA011926B1 (ru) 2009-06-30

Similar Documents

Publication Publication Date Title
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
UY26817A1 (es) Agentes antiinflamatorios selectivos de glucocorticoides
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
CR6563A (es) Compuestos sustitutos oxoazaheterocyclyl
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
ES2185606T3 (es) Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
EA200100022A1 (ru) Композиции с контролируемым высвобождением пароксетина
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
ATE406360T1 (de) Antagonisten der opioidrezeptoren
IS2227B (is) Blandan af serótónín endurupptökuhindra og 5-HT2Cmótlyfi, umsnúningsverka eða hlutaverka.
NO20043367L (no) Oralt farmasoytisk preparat
NO20063393L (no) Farmasoytiske preparater
RS53428B (en) COMPOSITIONS AND ANTI-VIRUS ACTIVITY OF SUBSTITUTED AZAINDOLOXOSCETER PIPERAZINE DERIVATIVES
ATE308522T1 (de) Opioidrezeptorantagonisten
UY26729A1 (es) Alquilaminas heterocíclicas como antagonistas de los receptores muscarínicos
BR0012951A (pt) Agonistas de retinóides seletivos
NO20013060D0 (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
EA200400280A1 (ru) Новые неочищенные и кристаллические формы гидрохлорида лерканидипина
CY1110572T1 (el) Στοματικο αντικαταθλιπτικο σκευασμα το οποιο περιλαμβανει ακετυλοσαλικυλικο οξυ για επιταχυνση της εναρξης δρασης
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
BR0013582A (pt) Agonistas retinóides seletivos para rar
RS50764B (sr) Farmaceutska kompozicija koja uključuje so mirtazapina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 31/00 , A61K 31/616 , A61P 25/24

Ipc: A61K 31/616 (2006.01), A61K 31/137 (2006.01), A61P

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2278 DE 02/09/2014.